文献速递白血病

氯法拉滨可替代蒽环类和依托泊苷用于儿童急性髓系白血病缓解诱导治疗:AML08多中心随机III期试验

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2019-06-27

AML08试验纳入285例儿童急性髓系白血病患者,随机接受Clo+AraC或HD-ADE方案诱导I治疗,主要终点为第22天MRD。结论提示氯法拉滨联合阿糖胞苷可能减少蒽环类和依托泊苷需求。

核心结论

  • 氯法拉滨联合阿糖胞苷用于缓解诱导可能减少儿童AML患者对蒽环类和依托泊苷的需求,并可能降低心肌病和治疗相关癌症的发生率。

研究设计与样本

  • 多中心随机III期试验,2008至2017年纳入285例患者,262例随机分配至Clo+AraC组(n=129)或HD-ADE组(n=133)接受诱导I治疗。

主要发现

  • 285例中263例(92.3%)经两疗程诱导后达完全缓解,诱导失败包括4例早期死亡和15例耐药白血病。

关键数值与推荐

  • 主要终点为第22天MRD,风险分类依据遗传学异常和MRD水平确定。
  • 诱导II为低剂量ADE单用或联合索拉非尼或伏立诺他,巩固治疗包括2-3个额外化疗疗程或造血干细胞移植。

临床怎么用

  • 氯法拉滨联合阿糖胞苷可作为儿童AML缓解诱导的替代方案,以减少蒽环类和依托泊苷暴露,但需注意MRD阳性率较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify effective and less toxic therapy for children with acute myeloid leukemia, we introduced clofarabine into the first course of remission induction to reduce exposure to daunorubicin and etoposide. PATIENTS AND METHODS: From 2008 through 2017, 285 patients were enrolled at eight centers; 262 were randomly assigned to receive clofarabine and cytarabine (Clo+AraC, n = 129) or high-dose cytarabine, daunorubicin, and etoposide (HD-ADE, n = 133) as induction I. Induction II consisted of low-dose ADE given alone or combined with sorafenib or vorinostat. Consolidation therapy comprised two or three additional courses of chemotherapy or hematopoietic cell transplantation. Genetic abnormalities and the level of minimal residual disease (MRD) at day 22 of initial remission induction determined final risk classification. The primary end point was MRD at day 22. RESULTS: Complete remission was induced after two courses of therapy in 263 (92.3%) of the 285 patients; induction failures included four early deaths and 15 cases of resistant leukemia. Day 22 MRD was positive in 57 of 121 randomly assigned evaluable patients (47%) who received Clo+AraC and 42 of 121 patients (35%) who received HD-ADE (odds ratio, 1.86; 95% CI, 1.03 to 3.41; P = .04). Despite this result, the 3-year event-free survival rate (52.9% [44.6% to 62.8%] for Clo+AraC v 52.4% [44.0% to 62.4%] for HD-ADE, P = .94) and overall survival rate (74.8% [67.1% to 83.3%] for Clo+AraC v 64.6% [56.2% to 74.2%] for HD-ADE, P = .1) did not differ significantly across the two arms. CONCLUSION: Our findings suggest that the use of clofarabine with cytarabine during remission induction might reduce the need for anthracycline and etoposide in pediatric patients with acute myeloid leukemia and may reduce rates of cardiomyopathy and treatment-related cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rubnitz JE, Lacayo NJ, Inaba H, et al. Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019. PMID: 31246522. doi:10.1200/JCO.19.00327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。